Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: A randomized controlled pilot trial

Journal of Trauma and Acute Care Surgery

Volumn 76, Issue 4, 2014, Pages 937-943

  Louis, Scott G ^a   Van, Philbert Y ^a   Riha, Gordon M ^a   Barton, Jeffrey S ^a   Kunio, Nicholas R ^a   Underwood, Samantha J ^a   Differding, Jerome A ^a   Rick, Elizabeth ^c   Ginzburg, Enrique ^b   Schreiber, Martin A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

deep venous thrombosis; enoxaparin; Thromboelastography

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ADULT; ANTITHROMBIN III DEFICIENCY; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84897097205     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000165     Document Type: Conference Paper

References (20)

1. Guyatt GH, Akl EA, Crowther M, Schunemann HJ, Gutterman DD, Zelman Lewis S. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141: 48SY52S.
2. OBrien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics. 2002;20:603-615.
3. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835-1846.
4. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, ColwellCW; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133: 381SY453S.
5. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331: 1601-1606.
6. Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention Of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141: E24SYe43S.
7. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther. 2007;29:2395-2405.
8. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707.
9. Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P. Prevention of venous thromboembolism after injury: An evidence-based reportVpart I: Analysis of risk factors and evaluation of the role of vena caval filters. J Trauma. 2000;49:132-138; discussion 139.
10. Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. J Trauma. 1997;42: 100-103.
11. Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma. 1996;41(3):446-459.
12. Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma. 2010;68:874-880.
13. Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, Pezold M, Lawrence J, BifflWL, Cothren CC, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146:764-772; discussion 772-774.
14. Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma. 2009;66: 1509-1517.
15. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004;351:1548-1563.
16. Ofosu FA, Blajchman MA, Modi G, Cerskus AL, Hirsh J. Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. Thromb Res. 1981;23:331-345.
17. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost. 2001;27:585-592.
18. Nast-Kolb D, Waydhas C, Gippner-Steppert C, Schneider I, Trupka A, Ruchholtz S, Zettl R, Schweiberer L, Jochum M. Indicators of the posttraumatic inflammatory response correlatewith organ failure in patients with multiple injuries. J Trauma. 1997;42:446-454; discussion 454-455.
19. Owings JT, Gosselin R. Acquired antithrombin deficiency following severe traumatic injury: Rationale for study of antithrombin supplementation. Semin Thromb Hemost. 1997;23(Suppl 1):17-24.
20. Rashid Q, Singh P, Abid M, Jairajpuri MA. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin. J Thromb Thrombolysis. 2012;34(2):251-259.